Danish pharmaceutical company H. Lundbeck A/S (CPH:HLUN-A) announced on Saturday the full results from the phase IV RESOLUTION trial.

The randomised, placebo-controlled trial was designed to evaluate the efficacy of eptinezumab versus placebo in patients with chronic migraine and associated medication-overuse headache who also received standardised patient education. Results were presented at the 11th Congress of the European Academy of Neurology taking place in Helsinki 21-24 June.

In the RESOLUTION trial, which included 608 participants with dual diagnoses of chronic migraine and medication-overuse headache (MOH), eptinezumab met the both the primary and secondary endpoints, showing significantly greater monthly migraine day (MMD) reductions through Weeks 1 to 4 with eptinezumab, compared to placebo. Across an average of 21 days, the change from baseline in MMDs was -6.9 with eptinezumab treatment, compared to -3.7 days for placebo (p